Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Entrada Therapeutics, Inc.

Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers BIIB TRDA
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports First Quarter 2025 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Announces $100 Million Registered Direct Offering
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports First Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Promotes Nathan J. Dowden to President
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Tickers TRDA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.